{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:11:44Z","timestamp":1791670304472,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ijrobp.2025.03.001","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T21:19:42Z","timestamp":1743369582000},"page":"1227-1237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Esophageal Toxicity After Dose-Escalated Radiation Therapy for Stage II-III Non-Small Cell Lung Cancer: A Secondary Analysis of the Phase 2 Randomized ARTFORCE PET-Boost Trial"],"prefix":"10.1016","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9549-5397","authenticated-orcid":false,"given":"Saskia A.","family":"Cooke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 S.A.","family":"Belderbos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Stam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Reymen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Lambrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gitte","family":"Fredberg Persson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Faivre-Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith M.T.","family":"Dieleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judi","family":"van Diessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"de Ruysscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Jakob","family":"Sonke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.03.001_bib0001","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0002","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ijrobp.2004.06.014","article-title":"Dosimetric and clinical predictors for radiation-induced esophageal injury","volume":"61","author":"Ahn","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0003","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.radonc.2013.08.017","article-title":"Severe late esophagus toxicity in NSCLC patients treated with IMRT and concurrent chemotherapy","volume":"108","author":"Chen","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0004","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ijrobp.2013.07.029","article-title":"Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: An individual patient data meta-analysis","volume":"87","author":"Palma","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0005","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non - small-cell lung cancer","volume":"28","author":"Aup\u00e9rin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0006","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","article-title":"Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): A randomised, two-by-two factorial p","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0007","doi-asserted-by":"crossref","first-page":"109492","DOI":"10.1016\/j.radonc.2023.109492","article-title":"18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial","volume":"181","author":"Cooke","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0008","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.radonc.2018.09.019","article-title":"The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial)","volume":"131","author":"van Diessen","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0009","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.radonc.2012.03.005","article-title":"The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer","volume":"104","author":"van Elmpt","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0010","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0959-8049(94)90535-5","article-title":"The EORTC QLQ-LC13: A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials","volume":"30","author":"Bergman","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0011","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1016\/j.ijrobp.2022.07.1501","article-title":"Whole tumor vs. FDG-directed dose escalation in patients with locally advanced NSCLC: Evaluation of isotoxic treatment plans from the randomized ARTFORCE PET-boost trial","volume":"114","author":"Cooke","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0012","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/j.ijrobp.2009.05.070","article-title":"Radiation dose-volume effects in the esophagus","volume":"76","author":"Werner-Wasik","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0013","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.prro.2017.07.010","article-title":"Dosimetric predictors for acute esophagitis during radiation therapy for lung cancer: Results of a large statewide observational study","volume":"8","author":"Paximadis","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0014","first-page":"597","article-title":"Advances in dosimetry and biological predictors of radiation-induced esophagitis","volume":"9","author":"Yu","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1118\/1.598063","article-title":"Reporting and analyzing dose distributions: A concept of equivalent uniform dose","volume":"24","author":"Niemierko","year":"1997","journal-title":"Med Phys"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib49","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.radonc.2012.09.024","article-title":"Relating acute esophagitis to radiotherapy dose using FDG-PET in concurrent chemo-radiotherapy for locally advanced non-small cell lung cancer","volume":"106","author":"Nijkamp","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0016","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.8548","article-title":"NRG-RTOG 1106\/ACRIN 6697: A phase IIR trial of standard versus adaptive (mid-treatment PET-based) chemoradiotherapy for stage III NSCLC\u2014Results and comparison to NRG-RTOG 0617 (non-personalized RT dose escalation)","volume":"39","author":"Kong","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0017","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG oncology RTOG 0617: Standard-versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer","volume":"38","author":"Bradley","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0018","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1470-2045(20)30013-9","article-title":"Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): A multicentre, open-label, randomised, controlled trial","volume":"21","author":"Nestle","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0019","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.lungcan.2018.06.020","article-title":"Dose escalation to 84 Gy with concurrent chemotherapy in stage III NSCLC appears excessively toxic: Results from a prematurely terminated randomized phase II trial","volume":"122","author":"Hallqvist","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0020","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210776","article-title":"Duration of acute esophageal toxicity in concomitant radio-chemotherapy for non-small cell lung cancer with different fractionation schedules","volume":"94","author":"Socha","year":"2021","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0021","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.ijrobp.2016.07.022","article-title":"Dose and fractionation in radiation therapy of curative intent for non-small cell lung cancer: Meta-analysis of randomized trials","volume":"96","author":"Ramroth","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0022","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s00066-012-0098-z","article-title":"Radiation-induced oesophagitis in lung cancer patients: Is susceptibility for neutropenia a risk factor?","volume":"188","author":"De Ruysscher","year":"2012","journal-title":"Strahlentherapie Und Onkologie"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0023","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1200\/JCO.2015.64.8824","article-title":"PROCLAIM: Randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer","volume":"34","author":"Senan","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0024","first-page":"70","article-title":"Excessive esophageal toxicity in patients with locally advanced non-small cell lung cancer treated with concurrent hypofractionated chemoradiotherapy and 3-weekly platinum doublet chemotherapy","volume":"36","author":"van der Voort van Zyp","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0025","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.radonc.2013.10.009","article-title":"Additional weekly cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: Efficacy and safety outcomes of a randomized, multi-center phase II study investigating","volume":"110","author":"van den Heuvel","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0026","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ijrobp.2018.07.188","article-title":"Concurrent daily cisplatin and high-dose radiation therapy in patients with stage III non-small cell lung cancer","volume":"102","author":"Dieleman","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0027","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.radonc.2019.07.028","article-title":"Safety and efficacy of reduced dose and margins to involved lymph node metastases in locally advanced NSCLC patients","volume":"143","author":"van Diessen","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0028","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.radonc.2015.08.010","article-title":"Multivariable normal-tissue complication modeling of acute esophageal toxicity in advanced stage non-small cell lung cancer patients treated with intensity-modulated (chemo-)radiotherapy","volume":"117","author":"Wijsman","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers14071833","article-title":"Radiation-induced esophagitis in non-small-cell lung cancer patients: Voxel-based analysis and NTCP modeling","volume":"14","author":"Monti","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0030","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.radonc.2016.01.007","article-title":"Acute esophagitis for patients with local-regional advanced non small cell lung cancer treated with concurrent chemoradiotherapy","volume":"118","author":"Pan","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0031","doi-asserted-by":"crossref","first-page":"6167","DOI":"10.2147\/OTT.S174561","article-title":"Clinical, dosimetric, and position factors for radiation-induced acute esophagitis in intensity-modulated (chemo)radiotherapy for locally advanced non-small-cell lung cancer","volume":"11","author":"Huang","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0032","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.radonc.2014.07.001","article-title":"Dosimetric predictors of esophageal toxicity after stereotactic body radiotherapy for central lung tumors","volume":"112","author":"Wu","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0033","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0034","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.annonc.2019.10.003","article-title":"Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer","volume":"31","author":"De Ruysscher","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103464","article-title":"Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: Interim analysis of overall survival from PACIFIC-R","volume":"9","author":"Filippi","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0036","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jtho.2020.10.129","volume":"16","author":"Peters","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0037","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1001\/jamaoncol.2021.2301","article-title":"Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer: The phase 2 KEYNOTE-799 nonrandomized trial","volume":"7","author":"Jabbour","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0038","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.ijrobp.2006.09.054","article-title":"Four-dimensional computed tomographic analysis of esophageal mobility during normal respiration","volume":"67","author":"Dieleman","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0039","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13014-021-01946-8","article-title":"Oesophageal IGRT considerations for SBRT of LA-NSCLC: Barium-enhanced CBCT and interfraction motion","volume":"16","author":"Woodford","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0040","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/j.prro.2020.06.006","article-title":"Quantifying the interfractional motion of esophagus using daily cone beam computed tomography with oral contrast during radiation therapy for locally advanced non-small cell lung cancer","volume":"10","author":"Qiu","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0041","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.prro.2023.04.014","volume":"13","author":"Heinzerling","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0042","article-title":"Lattice radiation therapy in clinical practice: A systematic review","volume":"39","author":"Iori","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0043","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1016\/j.ijrobp.2021.07.1253","article-title":"Lattice radiotherapy (LRT)-spatially fractionated radiotherapy (SFRT): Advanced non-small cell lung cancer (NSCLC): Early experience","volume":"111","author":"Larrea","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0044","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1016\/j.prro.2024.02.007","article-title":"Adapt-on-demand: A novel strategy for personalized adaptive radiation therapy for locally advanced lung cancer","volume":"14","author":"Li","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0045","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.radonc.2017.09.009","article-title":"Treating locally advanced lung cancer with a 1.5 T MR-Linac \u2013 Effects of the magnetic field and irradiation geometry on conventionally fractionated and isotoxic dose-escalated radiotherapy","volume":"125","author":"Bainbridge","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0046","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.ijrobp.2022.01.012","article-title":"Phase I study of accelerated hypofractionated proton therapy and chemotherapy for locally advanced non-small cell lung cancer","volume":"113","author":"Contreras","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0047","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ijrobp.2022.03.005","article-title":"Chemoradiation with hypofractionated proton therapy in stage II-III non-small cell lung cancer: A proton collaborative group phase 2 trial","volume":"113","author":"Hoppe","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.001_bib0048","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.radonc.2020.03.003","volume":"146","author":"Wang","year":"2020","journal-title":"Radiother Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625002287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625002287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T05:26:57Z","timestamp":1752643617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625002287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0360301625002287"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.03.001","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Esophageal Toxicity After Dose-Escalated Radiation Therapy for Stage II-III Non-Small Cell Lung Cancer: A Secondary Analysis of the Phase 2 Randomized ARTFORCE PET-Boost Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}